Yahoo Finance

FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia

• The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime ...
Monthly Prescribing Reference

FDA to Review Daridorexant for Insomnia Treatment

The FDA has accepted for review the NDA for daridorexant, an investigational dual orexin receptor, for the treatment of insomnia in adults. The Food and Drug Administration (FDA) has accepted for ...
Nasdaq

Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong

TOKYO, Jul 8, 2020 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic ...
PharmaTimes

Idorsia submits investigational insomnia treatment daridorexant to the EMA

Daridorexant is a dual orexin receptor agonist (DORA) designed for the treatment of insomnia Swiss biotech company Idorsia has submitted a marketing authorisation application to the European Medicines ...